Stock Market Reviews

MMSI (Merit Medical Systems, Inc.) News

Get the latest news, insights, and market updates on MMSI (Merit Medical Systems, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Merit Medical (MMSI) Upgraded to Buy: What Does It Mean for the Stock?
  Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Nov 21, 2025 - $MMSI
• Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
  The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
  Nov 19, 2025 - $MMSI
• 3 Small-Cap Stocks That Fall Short
  Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
  Nov 19, 2025 - $MMSI
• Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis
  SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery center (“ASC”) settings requires further consideration prior to CMS making a
  Nov 13, 2025 - $MMSI
• 3 Russell 2000 Stocks We Keep Off Our Radar
  Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
  Nov 13, 2025 - $MMSI
• Merit Medical Systems (MMSI): Evaluating Valuation Following Positive WRAPSODY Trial Results and Strong Q3 Performance
  Merit Medical Systems (MMSI) released encouraging 24-month efficacy data from its WAVE trial, highlighting the WRAPSODY device’s strong performance for hemodialysis patients. The company also reported third-quarter results that came in ahead of expectations. See our latest analysis for Merit Medical Systems. Backed by these recent clinical milestones and an earnings beat, Merit Medical Systems has seen momentum pick up, with a 10.8% share price return over the past month. However, longer-term...
  Nov 10, 2025 - $MMSI
• 1 Profitable Stock with Exciting Potential and 2 We Find Risky
  Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
  Nov 10, 2025 - $MMSI
• Merit Medical Systems’s Q3 Earnings Call: Our Top 5 Analyst Questions
  Merit Medical Systems delivered a positive third quarter, with results that exceeded Wall Street’s expectations and a strong market response. Management cited robust demand across the cardiovascular segment, meaningful progress in new product commercialization, and operational execution as the main drivers. President and CEO Martha Aronson highlighted the successful U.S. launch of the Prelude Wave hydrophilic sheath introducer and the ongoing market adoption of WRAPSODY CIE, emphasizing that “th
  Nov 6, 2025 - $MMSI
• Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
  The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 monthsThe clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI),
  Nov 5, 2025 - $MMSI
• Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
  At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous End
  Nov 3, 2025 - $MMSI